주요서비스 바로가기
본문 바로가기
매체정보 바로가기
로그인 바로가기
기사검색 바로가기
전체서비스 바로가기
Updated : Wednewsday, Aprill 24, 2024, 10:10
Home
Login
Sign in
한국어
National
Foreign Affairs
Central & Regional Affairs
Social Issues
Economics
Macro-Economics
Trade
Foreign Exchanges
Industries
ICT
Automobiles
Heavy & Chemical
Defence
Entertainment
Energy
Construction
Healthcare & Bio
Consumer
Services
Stock Market
Company & Stock Tracking
Market Trend & Outlook
Finance
Capital Market
Crypto
Banking
Insurances
Startups
Science/Tech
Science
New Tech
Blockchain
ESG
Environment
Social
Governance
Event
Exhibitions
Conferences
People
K-Culture
Cinema/Drama
K-pop
Food
Lifestyle
Arts/Culture
Opinion
Editorials
Contributions
Who's Who
기사검색
검색
All articles
List
Subject Type
Summary Type
Photo Type
Bio Industry: December US Prescription Data; Celltrion Group 4Q22 Earnings Preview
Finance
Park Pyeong-kuk
2023.01.16 18:09
Samsung Biologics: All Eyes on Plant 5 and Samsung Bioepis
이미지기사
Finance
Lee Dong-gun
2023.01.04 09:32
Samsung Biologics: Plant #4 to Contribute to Growth after Preparation Period in 2023
이미지기사
Finance
Park Pyeong-kuk
2023.01.04 09:23
Humira Biosimilar Market About to Open in the U.S.
이미지기사
Lifestyle
Jung Suk-yee
2022.12.13 12:28
Chong Kun Dang Publishes Clinical Results of LucenBS in International Journal
이미지기사
Lifestyle
Choi Moon-hee
2022.11.25 10:17
2023 Outlook: Bio: It’s Time for Biotech Firms to Outshine S&P500 Healthcare Players
Finance
Park Pyeong-kuk
2022.11.23 11:04
Celltrion Healthcare: Direct Sales to Begin in US
이미지기사
Finance
Park Pyeong-kuk
2022.11.14 13:12
Aprogen Bidding for cGMP Production Facility in the U.S.
이미지기사
Lifestyle
Choi Moon-hee
2022.11.02 13:36
Samsung Biologics: 3Q22 Earnings Beat Despite Raised Market Consensus
이미지기사
Finance
Kim Tae-hee
2022.10.28 09:21
Celltrion at Odds with British Government over 'Penalizing Rebate'
이미지기사
Lifestyle
Choi Moon-hee
2022.10.27 10:50
Samsung Biologics: To Benefit From FX Rates, Product Mix Improvement
이미지기사
Finance
Kim Tae-hee
2022.10.17 09:22
Bio Industry: GPM Improvement of 10%p Key for Competitiveness in US Biosimilar Market
Finance
Park Pyeong-kuk
2022.10.14 14:40
Pharmaceutical/bio: Limited Impact Expected from US Biotech Executive Order
Finance
Lee Dong-gun & Won Jae-hee
2022.09.22 09:08
Pharmaceutical/bio: Time for Momentum
Finance
Lee Dong-gun et al.
2022.09.07 09:01
Celltrion Healthcare: Prime Beneficiary of the Second Wave of Biosimilars
이미지기사
Finance
Kim Tae-hee
2022.08.31 09:22
Samsung Biologics: Inclusion of Samsung Bioepis to Boost Earnings
이미지기사
Finance
Kim Tae-hee
2022.08.31 09:18
Celltrion Healthcare: Conditions Met for a Virtuous Cycle Rally
이미지기사
Finance
Lee Dong-gun & Won Jae-hee
2022.08.18 11:55
Celltrion: Better Profitability, Increase in Remsima SC Market Share
이미지기사
Finance
Kim Tae-hee
2022.08.09 09:41
Celltrion: First Step toward a Virtuous Cycle Rally
이미지기사
Finance
Lee Dong-gun & Won Jae-hee
2022.08.09 09:35
Samsung Biologics: 2Q22 Review: Samsung Bioepis Fully Integrated
이미지기사
Finance
Park Pyeong-kuk
2022.08.01 09:00
처음
이전
이전
1
2
3
4
5
6
다음
다음
끝
위로
모바일버전
All articles
National
전체
Foreign Affairs
Central & Regional Affairs
Social Issues
Economics
전체
Macro-Economics
Trade
Foreign Exchanges
Industries
전체
ICT
Automobiles
Heavy & Chemical
Defence
Entertainment
Energy
Construction
Healthcare & Bio
Consumer
Services
Stock Market
전체
Company & Stock Tracking
Market Trend & Outlook
Finance
전체
Capital Market
Crypto
Banking
Insurances
Startups
Science/Tech
전체
Science
New Tech
Blockchain
ESG
전체
Environment
Social
Governance
Event
전체
Exhibitions
Conferences
People
K-Culture
전체
Cinema/Drama
K-pop
Food
Lifestyle
Arts/Culture
Opinion
전체
Editorials
Contributions
Who's Who
전체메뉴닫기